Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, initially developed for diabetes management, have recently demonstrated remarkable renal and cardiovascular protective effects in patients with non-diabetic CKD. This evidence concerns the gene SLC5A2 and diabetes mellitus.